Cue Health (Nasdaq: HLTH) is a healthcare technology company that puts consumers in control of their health information and places diagnostic information at the center of care.
Cue Health enables people to manage their health through real-time, actionable, and connected health information, offering individuals and their healthcare providers easy access to lab-quality diagnostics anywhere, anytime, in a device that fits in the palm of the hand. Cue Health’s first-of-its-kind COVID-19 test was the first FDA-authorized molecular diagnostic test for at-home and over-the-counter use without a prescription and physician supervision.
Outside the United States, Cue Health has received the CE mark in the European Union, Interim Order authorization from Health Canada, and regulatory approval from India’s Central Drugs Standard Control Organisation.
Cue was founded in 2010 and is headquartered in San Diego. For more information, please visit www.cuehealth.com.
Cue Health Reports First Quarter 2022 Results
May 11, 2022
SAN DIEGO--(BUSINESS WIRE)--May 11, 2022-- Cue Health Inc. (Nasdaq: HLTH), a healthcare technology company, (“Cue") today reported financial results for the first quarter of 2022. Recent Highlights Revenue of $179.4 million in the first...
Cue Health Makes De Novo Submission to FDA for Full Clearance of Its Molecular COVID-19 Test
May 02, 2022
SAN DIEGO, May 2, 2022 /PRNewswire/ -- Cue Health ("Cue") (Nasdaq: HLTH) today became the first company to submit to the U.S. Food and Drug Administration (FDA) for full clearance of its molecular COVID-19 test for at-home and point-of-care us...
SAN DIEGO--(BUSINESS WIRE)--Apr. 27, 2022-- Cue Health (“Cue”) (Nasdaq: HLTH), a healthcare technology company, announced today that it will release its first quarter 2022 financial results on Wednesday, May 11, 2022. In conjunction with th...